Donald M. Black

TL;DR: Atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.

TL;DR: Total serum triglyceride levels decreased in a dose-dependent manner, reductions in the 20-mg and 80-mg groups were statistically significant and atorvastatin did not cause a redistribution of triglycerides but consistently lowered triglycerides in all lipoprotein fractions.

TL;DR: A significantly greater number of patients with confirmed atherosclerosis treated with atorvastatin reached the target LDL cholesterol concentration at the starting dose than patients treated with fluvastasin or lovastatin, and significantly fewer (p < 0.05) patients treatment with colestipol required combination therapy with colstipol to achieve target cholesterol concentrations than all other statins tested.

TL;DR: Atorvastatin treatment had similar effects on plasma lipid levels in both men and women; however, the apoE gene locus was a significant predictor of LDL-C and TG responses to atorVastatin therapy in men, but not in women.

TL;DR: Atorvastatin caused significantly greater reductions from baseline than did simVastatin for LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, triglycerides, and apolipoprotein B (p <0.05); this cholesterol-lowering profile affords utility in many patient types.